20-F: Alpha Tau Medical Reports 2023 Annual Results, Highlights Clinical Progress

Alpha Tau Medical's 2023 annual report details financial performance and ongoing clinical trials for its Alpha DaRT technology.

Summary

• Alpha Tau Medical Ltd. released its annual report for the fiscal year ended December 31, 2023.
• The report highlights the company's focus on developing its Alpha DaRT technology for treating solid tumors.
• Alpha Tau has incurred significant losses since its inception in 2016, with net losses of $29.157 million in 2023 and an accumulated deficit of $115.759 million as of December 31, 2023.
• The company has not generated any revenue to date and expects to continue incurring losses for the foreseeable future.
• Alpha Tau is conducting multiple clinical trials to evaluate the safety and efficacy of Alpha DaRT for various cancer types.
• The company submitted a request to the PMDA in Japan for pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer and anticipates a response in the second half of 2024.
• Alpha Tau believes its existing cash and cash equivalents will fund operating expenses and capital expenditure requirements into 2026.
• The company is subject to extensive government regulation and oversight, both in the United States and abroad.
• Alpha Tau relies on third-party suppliers and CMOs, which exposes it to potential supply chain disruptions.
• The company is exploring strategic collaborations to augment its development and commercialization efforts.
• Alpha Tau is dependent on key personnel, and attracting and retaining qualified personnel is critical to its success.
• The company is incurring increased costs as a result of operating as a public company.
• Political, economic, and military conditions in Israel could materially and adversely affect the company's business.
• The company has 108 issued patents and 221 pending patent applications as of December 31, 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it highlights the potential of Alpha Tau's technology and ongoing clinical trials, it also acknowledges the company's significant losses, lack of revenue, and dependence on future funding. The risks associated with regulatory approvals, competition, and operating in Israel contribute to a neutral to slightly negative outlook.

Positives

• Alpha Tau is actively pursuing marketing authorization in the United States, Europe, and Japan.
• The company has a robust patent portfolio with 108 issued patents and 221 pending patent applications.
• Alpha Tau is exploring strategic partnerships to augment its development and commercialization efforts.
• The company is conducting a multi-center pivotal trial in the U.S. to evaluate Alpha DaRT in treating recurrent cutaneous squamous cell carcinoma tumors and anticipates completing recruitment in the second half of 2024 and receiving results in 2025.
• Alpha Tau is exploring strategic partnerships to augment its development and commercialization efforts.

Negatives

• Alpha Tau has incurred significant losses since its inception in 2016, with net losses of $29.157 million in 2023 and an accumulated deficit of $115.759 million as of December 31, 2023.
• The company has not generated any revenue to date and expects to continue incurring losses for the foreseeable future.
• Alpha Tau is subject to extensive government regulation and oversight, both in the United States and abroad.
• Alpha Tau relies on third-party suppliers and CMOs, which exposes it to potential supply chain disruptions.
• The company is incurring increased costs as a result of operating as a public company.
• Political, economic, and military conditions in Israel could materially and adversely affect the company's business.

Risks

• The company may need substantial additional funding, and if it is unable to raise capital when needed, it could be forced to delay, reduce or terminate the development of the Alpha DaRT technology or other product discovery and development programs or commercialization efforts.
• The commercial success of Alpha DaRT technology, if authorized or certified for commercial sale, will depend in part upon public perception of radiation therapies, and to a lesser extent, radiopharmaceuticals, and the degree of their market acceptance by physicians, patients, healthcare payors and others in the medical community.
• The market opportunities for Alpha DaRT technology may be smaller than anticipated or may be limited to those patients who are ineligible for or have failed prior treatments.
• If the company encounters difficulties enrolling patients in its clinical trials, its clinical development activities could be delayed or otherwise adversely affected.
• The company does not currently engage in commercial marketing activities or sales efforts and has no experience in marketing its products.
• If the company is unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell its Alpha DaRT technology, if approved or certified for commercial sale, it may not be able to generate product revenue.
• The company currently conducts and in the future intends to continue conducting pre-clinical studies, clinical trials for its Alpha DaRT technology outside the United States, and the FDA and similar foreign regulatory authorities may not accept data from such trials.
• The company may not receive, or may be delayed in receiving, the necessary marketing authorizations or certifications for its Alpha DaRT technology or any future products or product candidates, and failure to timely obtain necessary marketing authorizations or certifications for its product candidates would have a material adverse effect on its business.
• If the company does not obtain and maintain international regulatory registrations, marketing authorizations or certifications for any product candidates it develops, it will be unable to market and sell such product candidates outside of the United States.
• If in the future Alpha DaRT is approved or certified for commercial sale but the company is unable to obtain adequate reimbursement or insurance coverage from third-party payors, it may not be able to generate significant revenue.
• The company may be unable to obtain a sufficient or sufficiently pure supply of radioisotopes to support clinical development or at commercial scale.
• If the company is unable to obtain and maintain patent or other intellectual property protection for its Alpha DaRT technology and for any other products or product candidates that it develops, or if the scope of the patent or other intellectual property protection obtained is not sufficiently broad, its competitors could develop and commercialize products and technology similar or identical to ours, and its ability to commercialize any product candidates that it may develop, and its technology may be adversely affected.
• The company will continue to incur increased costs as a result of operating as a public company, and its management will continue to devote substantial time to new compliance initiatives.
• Conditions in Israel could materially and adversely affect the company's business.

Future Outlook

Alpha Tau expects to continue incurring significant expenses and operating losses for the foreseeable future as it continues clinical trials, seeks regulatory approvals, and develops its commercial infrastructure. The company believes its existing cash and cash equivalents will enable it to fund its operating expenses and capital expenditure requirements into 2026.

Industry Context

The announcement positions Alpha Tau Medical within the competitive landscape of oncology therapeutics, highlighting its focus on localized radiation therapy using alpha particles. The company faces competition from established pharmaceutical, medical device, and biotechnology companies, as well as academic research institutions, all striving to develop innovative cancer treatments.

Comparison to Industry Standards

• Alpha Tau's approach to cancer treatment using Alpha DaRT technology is relatively novel compared to traditional radiation therapies.
• Competitors like Varian Medical Systems and Elekta AB offer established radiation therapy systems, but Alpha Tau's technology focuses on the unique properties of alpha particles.
• Companies like Bayer and Novartis are developing targeted alpha-based radiopharmaceuticals for systemic cancer treatment, while Alpha Tau focuses on localized treatment.
• The company's clinical trial results, particularly the 100% overall response rate in a first-in-human study, are promising but need to be validated in larger, randomized trials.
• The company's ability to secure Breakthrough Device Designations from the FDA suggests that its technology has the potential to address unmet needs in cancer treatment.

Related Party Transactions

• The company has entered into employment or consulting agreements with each of its executive officers, and the terms of each individual's employment or service, as applicable, have been approved by the board of directors.
• Transactions with related parties also include employment agreements with relatives of certain directors or officers, each duly approved by the Board of Directors or its Audit Committee.

Stakeholder Impact

• Shareholders: The company's financial performance and future prospects will impact shareholder value.
• Employees: The company's ability to attract and retain qualified personnel is critical to its success.
• Patients: The development of Alpha DaRT technology has the potential to provide new treatment options for cancer patients.
• Customers: The company's ability to obtain regulatory approvals and reimbursement will impact the availability of its products to healthcare providers.
• Suppliers: The company's reliance on third-party suppliers exposes it to potential supply chain disruptions.

Next Steps

• Complete the ongoing U.S. clinical trial evaluating the efficacy and safety of Alpha DaRT in treating recurrent cutaneous squamous cell carcinoma tumors.
• Advance the global development pipeline by conducting feasibility studies in other tumors of high unmet need or metastatic diseases.
• Continue to evaluate the potential systemic immune response generated by the Alpha DaRT, particularly in combination with immunotherapies.
• Expand independent manufacturing capabilities across strategic geographical regions.
• Pursue marketing authorization and, if authorized, third-party payor coverage in multiple geographies, with a focus on the United States.

Key Dates

Keywords

Alpha DaRT, radiation therapy, solid tumors, clinical trials, oncology, medical device, cancer, Alpha Tau